ReCognitION, a new 1.3 M€ European project under the leadership of Peter-Bram ‘t Hoen, Baziel van Engelen and Jeffrey Glennon, was kicked-off in Gent. ReCognitION is an acronym for Recognition and Validation of Druggable Targets from the response to Cognitive Behaviour Therapy in Myotonic Dystrophy type 1 patients from Integrated -Omics Networks. The project is built on the successful OPTIMISTIC clinical trial. The OPTIMISTIC trial showed a positive effect of lifestyle interventions on the social participation and physical activity of Myotonic Dystrophy patients. In ReCognitION, Radboudumc will work with partners in Gent, Paris, Prague and Ottawa to understand the molecular pathways underlying the response to cognitive behavioural therapy and to identify drugs targeting these pathways that may consolidate or reinforce the effect of cognitive behavioural therapy.
ReCognitION was funded by ZON-MW and similar national funding organisations in Belgium, France, the Czech Republic and Canada under the eRARE program.
Related news items
Regional hospitals invest in joint research Four new projects have been granted29 October 2020
Four more research projects have been granted in the promotion fund of the Radboudumc and the regional hospitals.read more
Two studies show potential of trained immunity for the treatment of cancer Radboudumc makes Cell twice in one issue29 October 2020
Mihai Netea: "These studies show that stimulating trained immunity can have an important anti-cancer effect. In combination with current immunotherapy with 'checkpoint inhibitors', boosting trained immunity has the potential to significantly improve cancer treatment"read more
Research should facilitate discontinuation of antidepressants29 October 2020
How do you reduce the use of antidepressants safely and without major problems? That is a question that concerns many patients and physicians. Radboudumc and Amsterdam UMC in the Netherlands are going to investigate this with a ZonMw grant of 1.5 million euros.read more
Polyisocyanide Hydrogels as a Tunable Platform for Mammary Gland Organoid Formation28 October 2020
A multidisciplinary team of RIMLS and Radboud University researchers published in Advanced Science that Polyisocyanide Hydrogels as a Tunable Platform for Mammary Gland Organoid Formation.read more